- Approval Id
- b99e986cb149ceb9
- Drug Name
- Foster Pressurised Inhalation Solution 100mcg/6mcg per Actuation
- Product Name
- Foster Pressurised Inhalation Solution 100mcg/6mcg per Actuation
- Approval Number
- SIN13932P
- Approval Date
- 2011-03-15
- Registrant
- ORIENT EUROPHARMA PTE LTD
- Licence Holder
- ORIENT EUROPHARMA PTE LTD
- Drug Type
- Therapeutic
- Forensic Classification
- Prescription Only
- Dosage Form
- AEROSOL, METERED
- Dosage
- **Posology and method of administration**
Foster is for inhalation use.
Posology
**Asthma**
Foster is not intended for the initial management of asthma. The dosage of the components of Foster is individual and should be adjusted to the severity of the disease. This should be considered not only when treatment with combination products is initiated but also when the dose is adjusted. If an individual patient should require a combination of doses other than those available in the combination inhaler, appropriate doses of beta-2-agonists and/or corticosteroids by individual inhalers should be prescribed.
Beclometasone dipropionate in Foster is characterised by an extrafine particle size distribution which results in a more potent effect than formulations of beclometasone dipropionate with a non-extrafine particle size distribution (100 micrograms of beclometasone dipropionate extrafine in Foster are equivalent to 250 micrograms of beclometasone dipropionate in a non-extrafine formulation). Therefore, the total daily dose of beclometasone dipropionate administered in Foster should be lower than the total daily dose of beclometasone dipropionate administered in a non-extrafine beclometasone dipropionate formulation.
This should be taken into consideration when a patient is transferred from beclometasone dipropionate non-extrafine formulations to Foster; the dose of beclometasone dipropionate should be lower and will need to be adjusted to the individual needs of patients.
There are two treatment approaches:
1. **Maintenance therapy:** Foster is taken as regular maintenance treatment with a separate as needed rapid-acting bronchodilator.
2. **Maintenance and reliever therapy:** Foster is taken as regular maintenance treatment and as needed in response to asthma symptoms.
1. **Maintenance therapy**
Patients should be advised to have their separate rapid-acting bronchodilator available for rescue use at all times.
_**Dose recommendations for adults 18 years and above:**_
One or two inhalations twice daily.
The maximum daily dose is 4 inhalations daily.
2. **Maintenance and reliever therapy**
Patients take their daily maintenance dose of Foster and in addition take Foster as needed in response to asthma symptoms. Patients should be advised to always have Foster available for rescue use.
Foster maintenance and reliever therapy should especially be considered for patients with:
- not fully controlled asthma and in need of reliever medication
- asthma exacerbations in the past requiring medical intervention
Close monitoring for dose-related adverse effects is needed in patients who frequently take high numbers of Foster as-needed inhalations.
**Dose recommendations for adults 18 years and older:**
The recommended maintenance dose is 1 inhalation twice daily (one inhalation in the morning and one inhalation in the evening).
Patients should take 1 additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken.
**The maximum daily dose is 8 inhalations.**
Patients requiring frequent use of rescue inhalations daily should be strongly recommended to seek medical advice. Their asthma should be reassessed and their maintenance therapy should be reconsidered.
_**Dose recommendations for children and adolescents under 18 years:**_
**There is no experience with Foster in children and adolescents under 18 years of age. Therefore, Foster is not recommended for children and adolescents under 18 years until further data become available.**
Patients should be regularly reassessed by a doctor, so that the dosage of Foster remains optimal and is only changed on medical advice. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. When control of symptoms is maintained with the lowest recommended dosage, then the next step could include a test of inhaled corticosteroid alone.
Patients should be advised to take Foster every day even when asymptomatic.
**COPD**
**_Dose recommendations for adults 18 years and above:_**
Two inhalations twice daily.
Special patient groups:
There is no need to adjust the dose in elderly patients. There are no data available for use of Foster in patients with hepatic or renal impairment.
**Method of administration**
To ensure proper administration of the drug, the patient should be shown how to use the inhaler correctly by a physician or other health professional. Correct use of the pressurised metered dose inhaler is essential in order that treatment is successful.
Foster inhaler is provided with a counter on the back of the actuator, which shows how many doses are left. For the 120 doses presentation each time the patient press the canister, a puff of medicine is released and the counter counts down by one. Patients should be advised not to to drop the inhaler as this may cause the counter to count down.
Testing the inhaler
Before using the inhaler for the first time or if the inhaler has not been used for 14 days or more, the patient should release one actuation into the air in order to ensure that the inhaler is working properly. After testing the inhaler for the first time, the counter should read 120.
Whenever possible, patients should stand or sit in an upright position when inhaling from their inhaler.
Use of the inhaler
1. Patients should remove the protective cap from the mouthpiece and check that the mouthpiece is clean and free from dust and dirt or any other foreign objects.
2. Patients should breathe out as slowly and deeply as possible.
3. Patients should hold the canister vertically with its body upwards and put the lips around the mouthpiece without biting the mouthpiece.
4. At the same time, patients should breathe in slowly and deeply through the mouth. After starting to breathe in, they should press down on the top of the inhaler to release one puff.
5. Patients should hold the breath for as long as possible and, finally, they should remove the inhaler from the mouth and breathe out slowly. Patients should not breathe out into the inhaler.
To inhale a further puff, patients should keep the inhaler in a vertical position for about half a minute and repeat steps 2 to 5.
IMPORTANT: patients should not perform steps 2 to 5 too quickly.
After use, patients should close the inhaler with protective cap and check the dose counter.
Patients should be advised to get a new inhaler when the dose counter or indicator shows the number 20. They should stop using the inhaler when the counter shows 0 as any puffs left in the device may not be enough to release a full dose.
If mist appears following inhalation, either from the inhaler or from the sides of the mouth, the procedure should be repeated from step 2.
For patients with weak hands it may be easier to hold the inhaler with both hands. Therefore the index fingers should be placed on the top of the inhaler canister and both thumbs on the base of the inhaler.
Patients should rinse their mouth or gargle with water or brush the teeth after inhaling.
**Cleaning**
For the regular cleaning of the inhaler, patients should remove the cap from the mouthpiece and wipe the outside and inside of the mouthpiece with a dry cloth. They should not remove the canister form the actuator and should not use water or other liquids to clean the mouthpiece.
Patients who find it difficult to synchronise aerosol actuation with inspiration of breath, may use the AeroChamber Plus® spacer device. They should be advised by their doctor, pharmacist or a nurse in the proper use and care of their inhaler and spacer and their technique checked to ensure optimum delivery of the inhaled drug to the lungs. This may be obtained by the patients using the AeroChamber Plus® spacer device by one continuous slow and deep breath through the spacer, without any delay between actuation and inhalation.
- Route Of Administration
- RESPIRATORY (INHALATION)
- Indication Info
- **Therapeutic indications**
**Asthma**
Foster is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:
- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting beta2-agonist or
- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.
**COPD**
Symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
- Contraindications
- **Contraindications**
Known hypersensitivity to beclometasone dipropionate, formoterol fumarate dihydrate and/or any of the excipients.
- Atc Code
- R03AK07
- Atc Item Name
- formoterol and budesonide
- Pharma Manufacturer Name
- ORIENT EUROPHARMA PTE LTD
- Company Detail Path
- /organization/orient-europharma-pte-ltd
